GenSight Biologics obtains funding of €10 million from Sofinnova Partners, Invus and UPMC Enterprises

GenSight Biologics Provides Financial and Operational Update

Annual General Meeting on June 21, 2023

GenSight Biologics Withdraws its EMA Application for LUMEVOQ®

GenSight Biologics to Host a Webcast on April 5, 2023, to Provide an Update on LUMEVOQ® Manufacturing Following Investigations Findings

GenSight Biologics Reports Full Year 2022 Consolidated Financial Results

GenSight Biologics Provides Update on LUMEVOQ® Manufacturing and Commercialization Timelines

Rare Disease Day 2023: GenSight Biologics Raises Awareness of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to Present at Upcoming Investor Conferences

GenSight Biologics secures a €35 million credit facility from the European Investment Bank to support the launch of LUMEVOQ® in Europe